AbbVie Inc. (ABBV)
AbbVie sheds $38bn in value after failing schizophrenia drug trials
Pharma giant AbbVie Inc has disclosed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. The treatment did not show a significant reduction in the mental illness' symptoms compared to a placebo.
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
On Monday, AbbVie Inc ABBV stock is trading lower after it released data from its two Phase 2 EMPOWER trials of emraclidine for schizophrenia.
AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No ‘Significant' Improvement
Two trials of the company's experimental schizophrenia drug show no significant improvement in symptoms.
AbbVie's schizophrenia drug misses main goals of two trials
AbbVie said on Monday its experimental schizophrenia drug failed to meet the main goal of two mid-stage trials, sending its shares down more than 11% in premarket trading.
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks.
My Favorite Dividend King to Buy in November
This Dividend King truly wears the crown.
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Top 3 stocks to buy after Fed's 25-basis-point rate cut
US stocks remain resilient following the Federal Reserve's decision to lower its key interest rate by another 25 basis points on Thursday. According to the post-meeting statement: The Committee judges that the risks of achieving its employment and inflation goals are roughly in balance.
2 Dividend Kings That Would Have Doubled Your Money in 5 Years
You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.
Dividend Watch: Three Companies Boosting Quarterly Payouts
Earnings season continues to move at a rapid pace, with many companies reporting daily. And recently, these three companies delivered news of higher dividend payouts.
Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
